Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biology of emergent Salmonella exposed

01.12.2009
Deadly bug targets vulnerable children and adults in Africa

Researchers have characterised a new multi drug resistant strain of Salmonella Typhimurium that is causing life-threatening disease in Africa.


Salmonella typhimurium
This is a color-enhanced scanning electron micrograph. Credit: David Goulding, Wellcome Trust Sanger Institute

This type of Salmonella bug normally causes diarrhoea and is rarely fatal. The new strain infects vulnerable children and adults in many regions of sub-Saharan Africa leading to death in up to one in four cases.

The new genome work, a collaboration between the Wellcome Trust Sanger Institute, the Malawi-Liverpool-Wellcome Trust Clinical Research Programme and the Kemri-Wellcome Trust Programme, shows how genetic changes transformed this infection into a new antibiotic-resistant form of the disease. The new strain, called ST313, appears to be better adapted to affect humans, is resistant to several commonly used antibiotics and may spread from person to person.

The severe effects of ST313 - invasive disease and high mortality rates - are seen predominantly in individuals with the immune compromising conditions, HIV, malaria, malnutrition or anaemia. Until today, it had been widely assumed that this wasn't a new deadly form of the organism but, rather, that the existing diarrhoea-causing strain of the pathogen was taking advantage of the weakened immune system of patients with underlying health problems to cause a more severe disease.

Today's results paint a truer picture

"Multi-drug resistant forms of this deadly type of S. Typhimurium emerged only in the last decade," explains Dr Robert Kingsley from the Sanger Institute and lead author on the paper. "It seems to have evolved to acquire a unique armoury that allows it to efficiently infect vulnerable children and adults in some African regions. The results highlight the power of in-depth genome sequence analysis to challenge basic medical assumptions and distinguish closely related pathogens.

"This is a new form of pathogen."

The team studied approximately 50 samples of the bacterial DNA, extracted from blood samples of African patients with severe symptoms of infection and also suffering HIV, malaria, malnutrition or anaemia. They used these samples to produce a high-quality reference genome sequence. Based on this sequence, the team were able to look in fine detail at the genetic differences between ST313 and strains associated with milder disease symptoms across the globe.

"This work was entirely dependent on close collaboration that brings important samples collected over years together with genomic technology that can pick apart the important changes," says Professor Rob Heyderman, Director of the Malawi-Liverpool-Wellcome Trust, Clinical Research Programme. "This work is a great example of such cooperation: now we must build the capacity to expand this kind of research in affected countries."

"When we started looking in detail at our newly completed reference genome sequence, we saw the genetic signatures that suggested it may be adapting to humans," explains Dr Robert Kingsley. "For example, this deadly strain has lost around one in 50 of the genes found in the 'typical' S. Typhimurium - a classic sign that it may be becoming more closely adapted to one host, in this case, humans.

"We also found similar patterns of genome degradation in ST313 compared S. Typhi - a bacterium which is known to be well adapted to its human host."

Six out of ten of the regions that showed degradation in the invasive ST313 are also degraded in S. Typhi, suggesting that the genomes have converged in their ability to thrive in the human host. This theory is bolstered by the finding that eroded areas of the genome tend to play important roles in the intimate interaction with cells of the human host.

The team's findings suggest that ST313 may be spreading by a new method, not seen before in S. Typhimurium. This pathogen normally circulates among animals and is introduced to humans through food poisoning. It spends much of its time in the animal hosts. However, ST313 may be passing predominantly from person to person and so can adapt more rapidly to its human hosts: it doesn't spend time acquiring mutations to help it thrive in the animal host, but on the contrary may be losing them. This is likely to have helped seal its success and helped it to become the dominant strain among humans.

Multi drug resistant ST313 has swept through humans in remarkable fashion: in an 18-month period beginning in 2002, it came to represent 95 per cent of S. Typhimurium isolates identified in Africa. However, antibiotic-sensitive versions of the same strain may have been evolving in regions of Africa for many decades.

"This new strain of S. Typhimurium has rapidly gained resistance to many of the commonly used antibiotics in the field," explains Dr Chisomo Msefula from the Malawi-Liverpool-Wellcome Trust Clinical Research Programme. "Our findings show that ST313 has acquired a block of genes that make it resistant to the common antibiotics. The genes jumped into ST313 on a mobile genetic element called a transposon, bringing with it additional genes that make the strain more deadly."

"Even when treated using drugs against which the bacterium has not gained resistance, the mortality rate remains staggeringly high, at 25 per cent."

The team hope that the new sequence will open the door for future studies of disease important to populations in Africa

"There are more than 2500 different strains of Salmonella," explains Professor Gordon Dougan from the Sanger Institute and senior author on the paper. "The emergence and rise to dominance of ST313 in Africa is associated with uniquely susceptible host populations: we must be on our guard against the emergence of new pathogens in a rapidly changing world. This isn't simply a story about HIV infection: There is little evidence that this type of disease is a problem in other areas of the world where HIV and malaria infection rates are high, such as southeast Asia.

"If we can understand what's special about the types of Typhimurium that emerge and susceptible populations, we might be able to predict in future where new pathogens will emerge. We may also be able to design vaccines against those pathogens."

Two ST313 isolates in available databases come from outside Africa - one from India and one from the UK. Strikingly, both were from severe invasive disease. Invasive cases are very, very rare outside certain regions of Africa. The researchers don't know whether the additional cases were from travellers to Africa or know the immune status of the patients.

Tracking the transmission pathways and the emergence of new strains can most effectively be done using new sequencing technologies to spot the tiny differences - single letter changes - in the genetic code. The completion of this new high-quality S. Typhimurium reference genome for the emergent ST313 strain opens the door for such investigations in the future.

Notes to Editors

Publication Details
Kingsley RA et al. (2009) Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Research.
Funding
This work was supported by The Wellcome Trust and the Scientific Foundation of Ireland.

Participating Centres

The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
Department of Molecular Biology, Max-Planck Institute for Infection Biology, Berlin, Germany
Kenya Medical Research Institute–Wellcome Trust Collaborative Project, Kilifi, Kenya
Environmental Research Institute and Department of Microbiology, University College Cork, Cork, Ireland
Department of Bacteriology, National University of Ireland, Galway, Ireland
Medical Research Council Centre for Immune Regulation, Institute of Biomedical Research, The Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom

The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.

The Malawi-Liverpool-Wellcome Trust Programme is a leading laboratory-based health research institution led by Malawian and international Scientists in partnership with the University of Malawi College of Medicine. MLW conducts internationally competitive research aimed at improving the health of people in Malawi and elsewhere in the Region. MLW hosts a comprehensive programme of professional development for the research leaders of the future.

The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing.

Contact details
Don Powell Press Officer
Wellcome Trust Sanger Institute
Hinxton, Cambridge, CB10 1SA, UK
Tel +44 (0)1223 496 928
Mobile +44 (0)7753 7753 97
Email press.officer@sanger.ac.uk

Don Powell | EurekAlert!
Further information:
http://www.sanger.ac.uk
http://www.mlw.medcol.mw
http://www.wellcome.ac.uk

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>